ArticleJAMA network open2026
Mismatched Unrelated vs Matched Related Donor Transplant With Posttransplant Cyclophosphamide Among Patients With Blood Cancers.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Relapse limits survival after allogeneic hematopoietic cell transplant. Although human leukocyte antigen-matched related donors (MRDs) are traditionally preferred, mismatched unrelated donors (MMUDs) using posttransplant cyclophosphamide may provide stronger graft-vs-leukemia effects, potentially altering donor selection strategies. Objective: To compare outcomes between MRD and MMUD transplant in the posttransplant cyclophosphamide era and assess whether MMUD grafts are associated with lower relapse rates. Design, Setting, and Participants: This retrospective cohort study (January 1, 2017, to August 31, 2024) assessed 1038 patients with acute leukemia or myelodysplastic syndromes and/or myeloproliferative neoplasms undergoing their first peripheral blood hematopoietic cell transplant using posttransplant cyclophosphamide. The MRD cohort was from a single tertiary center, and the MMUD cohort was from the Center for International Blood and Marrow Transplant Research. Data were analyzed between January 19, 2026, and April 2, 2026. Exposure: Transplant from MRD (n = 306) vs MMUD (n = 732). Main Outcomes and Measures: Disease-free survival (DFS), overall survival (OS), relapse, nonrelapse mortality, and graft-vs-host disease (GVHD). The study used inverse probability of treatment weighting with overlap weights and bootstrapping to address structural confounding, particularly donor age. Cox proportional hazard models were used to compare outcomes between groups and confirm that phrasing with the author. Results: Among 1038 patients (526 [50.7%] female), donors in the MRD group were older (median [IQR] age, 57 [45-64] years) than in the MMUD group (median [IQR] age, 28 [24-35] years) (P < .001). Recipient age was similar (median [IQR] age, 60 [47-66] vs 58 [47-65] years; P = .40). In patients with a high or very high Disease Risk Index (DRI), MMUD transplant was associated with significantly lower relapse hazard vs MRD (weighted hazard ratio [HR], 0.56; 95% CI, 0.33-0.94; P = .03), although DFS (HR, 0.71; 95% CI, 0.46-1.11; P = .14) and OS (HR, 0.85; 95% CI, 0.53-1.37; P = .51) were similar. Conversely, in patients with low to intermediate DRIs, hazard estimates for DFS (HR, 1.24; 95% CI, 0.92-1.66; P = .16) and OS (HR, 1.36; 95% CI, 0.99-1.88; P = .06) lacked precision. MMUD was associated with lower risk of grade III to IV acute GVHD (HR, 0.56; 95% CI, 0.32-0.98; P = .04) but higher chronic GVHD (HR, 2.82; 95% CI, 2.02-3.95; P < .001). Conclusions and Relevance: In this cohort study, MMUD transplant was associated with lower relapse rates compared with MRD in patients with high-risk malignant tumors, potentially reflecting enhanced alloreactivity, although accompanied by increased chronic GVHD. These findings indicated that the immunologic role of human leukocyte antigen mismatch varies by disease risk, suggesting that MMUD grafts offered a distinct risk-benefit profile that warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.